急性白血病患者多重耐药基因检测的临床意义  

Clinical Significance of Detection of Multidrug Resistance Gene1 Expression in Acute Leukemia

作　　者：王春燕[1] 姜振宇[1] 姚程[1] 李舜华[1] 袁长吉[1] 张福明[1] 

机构地区：[1]吉林大学第一医院血液肿瘤科,吉林长春130021

出　　处：《吉林大学学报（医学版）》2003年第4期425-427,共3页Journal of Jilin University：Medicine Edition

基　　金：国家自然基金资助项目 (391 70 36 6 )

摘　　要：目的 :结合临床化疗效果探讨白血病多重耐药 ( mdr)的诊断方法。方法 :采用流式细胞术检测白血病细胞内药物浓度和原位杂交技术检测白血病 mdr基因的表达。结果 :1 2例难治及复发患者柔红霉素 ( DNR)的平均浓度为 ( 4 4.80± 7.74) %,而 1 0例初治完全缓解患者 DNR的浓度为( 80 .0 1± 2 .1 0 ) %,两组比较差异有显著性 ( P<0 .0 1 ) ,且 1 2例难治及复发患者 mdr1基因表达结果除 4名阴性外 ,其他均为阳性 ,而 1 0例初治完全缓解患者 mdr1基因表达均为阴性。结论 :两种检测方法联合检测白血病 mdr,能初步筛选急性白血病 mdr的类型 。Objective: To study diagnosing method of multidrug resistance with leukemia combining clinical chemotherapy effect. Methods:Intracellular medication concentration was examined in patients with leukemia by flow cytometry and relative expression levels of mdr1 which was estimated by RNA in situ hybridization. Results: Average intracellular DNR accumulation in refractory and relapsing patients(4/12 mdr1 expression negative) was (44.80±7.74)%, but that in newly diagnosed and treated patients(10/10 mdr1 expression negative) with remission was (80.01±2.10)%. Intracellular DNR accumulation in newly diagnosed and treated patients with remission were significantly higher than that in refractory and relapsing patients ( P <0.01). Conclution: Mdr1 detection by the two above mentioned methods could filter the type of multidrug resistance in patients with leukemia and could help to project the clinical chemotherapy schedule.

关 键 词：白血病/药物疗法 多重耐药 急性病 

分 类 号：R733.7[医药卫生—肿瘤] R915[医药卫生—临床医学]